June 23, 2018 — Today, Socium Therapeutics announced that Debasish Roychowdhury, PhD has joined the company’s Scientific Advisory Board. Dr. Roychowdhury is a medical oncologist with over 15 years of comprehensive pharmaceutical industry and senior management experience and over 14 years of patient care, academic research and teaching experience. Dr. Roychowdhury is a leader in the pharmaceutical industry across multiple functional and cross-functional areas, regions and matrices, including – all stages of R&D, regulatory, commercial operations and medical affairs, market access, business development and alliance management. Dr. Roychowdhury was involved in nine new drug approvals in the US and EU and other markets and numerous supplemental approvals.
Dr. Roychowdhury is currently the Chief Medical Officer for Partner Therapeutics, Inc., a biotechnology company focused on cancer treatments. Prior to joining Partner Therapeutics, Dr. Roychowdhury was one of the founding members of the Seragon Clinical and Scientific Advisory Board and was the company’s Chief Medical Officer where he played a key role in the development and advancement of Seragon’s selective estrogen receptor degrader (SERD) platform for breast cancer and other hormone-driven cancers until the company was acquired by Roche in August 2014. Prior to Seragon, Dr. Roychowdhury was the Senior Vice President and Head of the Global Oncology Division at Sanofi until November 2013. Prior to that, he served as the Vice President for Clinical Development at GlaxoSmithKline and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences and University of California, San Francisco. Dr. Roychowdhury is a member of the Board of Directors for Partner Therapeutics, Lytix Biopharma AS, Celyad S.A., and Fund+, a life sciences investment fund.